New Daily Persistent Headache (NDPH) — A Rare Diagnosis That Is Easy to Misapply
G44.52 produces automatic PA denial for CGRP mAbs and Botox — if the patient has a prior migraine history, correct the code to G43.7xx before submitting.
PA impact: This card directly affects prior authorization outcomes. Documentation language from this card can be used in PA letters and appeals.
What NDPH is and why the name is the problem
New daily persistent headache (NDPH) has a population prevalence of 0.03–0.1%. The name sounds descriptively accurate for any patient with a continuous headache, causing ICD-10 code G44.52 to be applied far more often than the underlying condition actually occurs. This matters because G44.52 has no FDA-approved treatments — payers do not recognize it as an indication for CGRP monoclonal antibodies or onabotulinumtoxinA. Filing a prior authorization under G44.52 produces an automatic denial.
The ICHD-3 diagnostic test: three questions
Question 1: Can the patient identify the exact day the headache began? NDPH requires a clearly remembered onset — not a gradual worsening, not "it's been getting worse for months." The patient should be able to say "It started on March 14th."
Question 2: Was there no prior escalating headache history? NDPH arises de novo. A patient with a history of episodic migraine that gradually increased in frequency until it became daily does not have NDPH — they have chronic migraine (G43.7xx).
Question 3: Has it been truly unremitting since onset? NDPH is continuous from the start — daily or near-daily headache present from within 24 hours of onset, persisting without remission.
If any answer is "no," NDPH is unlikely and chronic migraine (G43.7xx) should be the working diagnosis.
The ICHD-3 default rule that causes the most errors
When both NDPH and chronic migraine criteria are technically fulfilled, the ICHD-3 default classification is NDPH — unless the clinician can establish that the headache evolved gradually from episodic migraine. This override condition is the common point of failure. Clinicians who see a patient with daily headache and a remembered onset date apply G44.52 without checking whether the patient also has a prior migraine history that explains the progression. The correct approach: if there is any history of escalating episodic migraine, chronic migraine (G43.7xx) is the appropriate code regardless of how clearly the patient remembers when the headache became daily.
PA consequences
Critical coding alert
G44.52 = automatic PA denial for CGRP mAbs and Botox. These medications require G43.xxx migraine codes.
If a patient has been coded G44.52 but meets chronic migraine criteria, correct the code BEFORE submitting any PA.
Correction template
Note language for overriding a prior G44.52:
"Patient was previously coded G44.52 (new daily persistent headache). On review, clinical history reveals [escalating episodic migraine pattern / prior migraine diagnosis / gradual frequency increase from X to Y days per month over Z months]. This history is consistent with chronic migraine (ICHD-3 1.3) rather than NDPH (ICHD-3 4.10). Diagnosis updated to G43.709 (chronic migraine without aura, not intractable, without status migrainosus). Prior authorization for [medication] is being submitted under the corrected diagnosis."
Secondary causes to rule out
True NDPH is a primary headache disorder. Before applying this diagnosis, secondary causes of new-onset daily headache must be excluded: intracranial hypertension (idiopathic or secondary), spontaneous CSF leak, cerebral venous sinus thrombosis (CVST), and structural lesions. Imaging and opening pressure measurement are indicated when the presentation is acute-onset daily headache without prior headache history.
Ready to run a PA?
The PA Engine applies this guidance automatically — paste a clinical note and get a complete, payer-specific PA letter in under a minute. Free, no account required.
Run a PA — free →Citations: ICHD-3 Section 4.10 (New Daily Persistent Headache) — ichd-3.org | Robbins MS et al., Curr Pain Headache Rep 2010;14(1):97-102 | Evans RW, Rozen TD, Neurology 2001;57(10):1921-1923.